Advanced Life Sciences Holdings, Inc. , today announced that the U.S. FDA has accepted and filed the Company's New Drug Application (NDA) for cethromycin, a novel once-a-day oral antibiotic, for the treatment of mild-to-moderate community acquired pneumonia. The FDA has established a goal of a standard 10-month review such that the anticipated target action date of the cethromycin NDA would be July 31, 2009.
The details can be read here.
No comments:
Post a Comment